Fachrepositorium Lebenswissenschaften

9 Treffer

Suche

Publisso-Menue

Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer

2024 . Uhlenbruch, Mark | Krüger, Stefan

Prognostic value of metabolic tumor volume on [18F]FDG PET/CT in addition to the TNM classification system of locally advanced non-small cell lung cancer

2024 . Brose, Alexander | Miederer, Isabelle | König, Jochem | Gkika, Eleni | Sahlmann, Jörg | Schimek-Jasch, Tanja | Schreckenberger, Mathias | Nestle, Ursula | Kappes, Jutta | Miederer, Matthias

Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

2024 . Li, Yutao | Sharma, Amit | Schmidt-Wolf, Ingo G.H.

First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis

2023 . Hofstetter, Kerstin | Taugner, Julian | Käsmann, Lukas | Mansoorian, Sina | Flörsch, Benedikt | Eze, Chukwuka | Tufman, Amanda | Reinmuth, Niels | Duell, Thomas | Belka, Claus | Manapov, Farkhad

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions

2021 . Eze, Chukwuka | Schmidt-Hegemann, Nina-Sophie | Sawicki, Lino Morris | Kirchner, Julian | Roengvoraphoj, Olarn | Käsmann, Lukas | Mittlmeier, Lena M. | Kunz, Wolfgang G. | Tufman, Amanda | Dinkel, Julien | Ricke, Jens | Belka, Claus | Manapov, Farkhad | Unterrainer, Marcus

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition

2021 . Unterrainer, Marcus | Taugner, Julian | Käsmann, Lukas | Tufman, Amanda | Reinmuth, Niels | Li, Minglun | Mittlmeier, Lena M. | Bartenstein, Peter | Kunz, Wolfgang G. | Ricke, Jens | Belka, Claus | Eze, Chukwuka | Manapov, Farkhad

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

2021 . Taugner, Julian | Käsmann, Lukas | Karin, Monika | Eze, Chukwuka | Flörsch, Benedikt | Guggenberger, Julian | Li, Minglun | Tufman, Amanda | Reinmuth, Niels | Duell, Thomas | Belka, Claus | Manapov, Farkhad

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients

2021 . Taugner, Julian | Käsmann, Lukas | Eze, Chukwuka | Rühle, Alexander | Tufman, Amanda | Reinmuth, Niels | Duell, Thomas | Belka, Claus | Manapov, Farkhad

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

2020 . Bozorgmehr, Farastuk | Chung, Inn | Christopoulos, Petros | Krisam, Johannes | Schneider, Marc A. | Brückner, Lena | Mueller, Daniel Wilhelm | Thomas, Michael | Rieken, Stefan